XTL Biopharmaceuticals Ltd. (TLV: XTLB)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
6.30
+0.40 (6.78%)
Jan 19, 2025, 3:49 PM IDT
80.00%
Market Cap 55.53M
Revenue (ttm) 171.00K
Net Income (ttm) -3.93M
Shares Out 881.39M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,998,717
Average Volume 3,214,985
Open 5.90
Previous Close 5.90
Day's Range 5.60 - 6.30
52-Week Range 0.03 - 6.30
Beta 1.05
RSI 51.26
Earnings Date Mar 26, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.